News

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both…

2 years ago

INTERIM REPORT FOR Q1 2023/24

In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven…

2 years ago

PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy

               Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing…

2 years ago

BioSenic patent granted in Canada for broader protection of ATO therapeutic platform

PRESS RELEASE – INSIDE INFORMATION    BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter…

2 years ago

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong…

2 years ago

Safe Supply Streaming Co. Announces Significant Milestone for Portfolio Company CannaLabs: Health Canada Inspection for Dealer License

Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - Safe Supply Streaming Co. Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe…

2 years ago

Medexus Schedules Third Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host…

2 years ago

CloudMD Demonstrates a Customer Focused Commitment to Profitable Business Growth Delivered with Efficiency

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - CloudMD Software & Services Inc. (TSXV: DOC) (OTCQX: DOCRF) (FSE: 6PH)…

2 years ago

MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients

VANCOUVER, BC / ACCESSWIRE / January 30, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), announces it is…

2 years ago

BioNxt Solutions Announces Closing of Final Tranche of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, BC / ACCESSWIRE /…

2 years ago